US7599161095 - Common Stock

We assign a fundamental rating of **5** out of 10 to **RGEN**. **RGEN** was compared to 61 industry peers in the **Life Sciences Tools & Services** industry. While **RGEN** has a great health rating, its profitability is only average at the moment. **RGEN** is valied quite expensively at the moment, while it does show a decent growth rate.

Each year in the past 5 years **RGEN** has been profitable.

Of the past 5 years **RGEN** 4 years had a positive operating cash flow.

With a decent **Return On Assets** value of **4.61%**, **RGEN** is doing good in the industry, outperforming **77.05%** of the companies in the same industry.

Looking at the **Return On Equity**, with a value of **5.82%**, **RGEN** is in the better half of the industry, outperforming **77.05%** of the companies in the same industry.

With a decent **Return On Invested Capital** value of **1.95%**, **RGEN** is doing good in the industry, outperforming **67.21%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.61% | ||

ROE | 5.82% | ||

ROIC | 1.95% |

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

The **Profit Margin** of **RGEN** (**17.29%**) is better than **86.89%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 8.34% | ||

PM (TTM) | 17.29% | ||

GM | 46.78% |

OM growth 3Y-24.87%

OM growth 5Y-10.52%

PM growth 3Y-26.44%

PM growth 5Y-5.32%

GM growth 3Y-7.98%

GM growth 5Y-4.25%

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), **RGEN** is destroying value.

There is no outstanding debt for **RGEN**. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

An Altman-Z score of **13.22** indicates that **RGEN** is not in any danger for bankruptcy at the moment.

With an excellent **Altman-Z score** value of **13.22**, **RGEN** belongs to the best of the industry, outperforming **95.08%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0 | ||

Debt/FCF | 2.93 | ||

Altman-Z | 13.22 |

ROIC/WACC0.17

WACC11.75%

A Current Ratio of **2.69** indicates that **RGEN** has no problem at all paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.69 | ||

Quick Ratio | 2.11 |

The **Earnings Per Share** has been growing by **18.51%** on average over the past years. This is quite good.

EPS 1Y (TTM)-39%

EPS 3Y1.39%

EPS 5Y18.51%

EPS growth Q2Q-70.13%

Revenue 1Y (TTM)-16.39%

Revenue growth 3Y20.37%

Revenue growth 5Y26.91%

Revenue growth Q2Q-29.65%

The **Earnings Per Share** is expected to grow by **24.02%** on average over the next years. This is a very strong growth

Based on estimates for the next years, **RGEN** will show a quite strong growth in **Revenue**. The Revenue will grow by **13.66%** on average per year.

EPS Next Y4.51%

EPS Next 2Y24.02%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year3.7%

Revenue Next 2Y11.08%

Revenue Next 3Y13.66%

Revenue Next 5YN/A

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

Based on the **Price/Earnings** ratio, **RGEN** is valued a bit cheaper than 63.93% of the companies in the same industry.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **RGEN** indicates a somewhat cheap valuation: **RGEN** is cheaper than 60.66% of the companies listed in the same industry.

The average S&P500 **Price/Forward Earnings** ratio is at **21.63**. **RGEN** is valued rather expensively when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 94.48 | ||

Fwd PE | 108.69 |

62.30% of the companies in the same industry are more expensive than **RGEN**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 112.42 | ||

EV/EBITDA | 86.24 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates **RGEN** does not grow enough to justify the current Price/Earnings ratio.

A more expensive valuation may be justified as **RGEN**'s earnings are expected to grow with **24.02%** in the coming years.

PEG (NY)20.93

PEG (5Y)5.1

EPS Next 2Y24.02%

EPS Next 3YN/A

No dividends for **RGEN**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**REPLIGEN CORP**

NASDAQ:RGEN (2/23/2024, 7:08:58 PM)

After market: 196.52 0 (0%)**196.52**

**+3.12 (+1.61%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap10.97B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 94.48 | ||

Fwd PE | 108.69 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)20.93

PEG (5Y)5.1

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.61% | ||

ROE | 5.82% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 8.34% | ||

PM (TTM) | 17.29% | ||

GM | 46.78% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.27

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.69 | ||

Quick Ratio | 2.11 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-39%

EPS 3Y1.39%

EPS 5Y

EPS growth Q2Q

EPS Next Y4.51%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-16.39%

Revenue growth 3Y20.37%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y